Rhythm Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Rhythm Pharmaceuticals (RYTM).

Price Target Range — 10 Quarters

Analyst Consensus — 18 Analysts

2S.Buy

15Buy

1Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$132Upside to Avg. PT+46.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$155→$159
Sep 14, 2026	Leerink Partners	—	Assumes	Outperform	$133
Aug 28, 2026	Deutsche Bank	David Hoang	Initiate	Hold	$120
Aug 7, 2026	JP Morgan	Priyanka Grover	PT Raise	Overweight	$145→$146
Aug 5, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$142→$143
Aug 5, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$141→$155
Aug 5, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$155→$160
Jul 27, 2026	JP Morgan	Priyanka Grover	Initiate	Overweight	$145
Jul 7, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$137→$141
Jun 16, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$143→$151
Jun 15, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$144→$155
May 7, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$140→$143
May 6, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$136→$137
May 6, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$143→$144
Mar 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$100→$105
Mar 20, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$131→$142
Mar 20, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$139→$149
Mar 20, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$152→$155
Mar 18, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$110→$100
Mar 17, 2026	Citigroup	Samantha Semenkow	PT Cut	Buy	$136→$131

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $155 to $159.

Benzinga Newsdesk

PRO
Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120

Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Hold rating and announces Price Target of $120.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $145 to $146.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $142 to $143.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $141 to $155.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160

Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $155 to $160.

Benzinga Newsdesk

Rhythm Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Rhythm Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159

PRO
Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120

PRO
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

PRO
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

PRO
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160

People Also Watch

People Also Watch

Rhythm Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Rhythm Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159

PRODeutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120

PROJP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

PROCitigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

PRORBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

PROCitizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159

PRO
Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120

PRO
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

PRO
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

PRO
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160